Innovative strategies for hepatitis C in Belgium integrating treatment efficacy, public disease burden, and healthcare costs
Summary No abstract available. Countries: Belgium Read the Full Report
-
-
Burden of disease and cost of chronic hepatitis C infection in Canada
Summary Background Chronic infection with hepatitis C virus (HCV) is a major cause of cirrhosis, hepatocellular carcinoma and liver transplantation. Objective To estimate the burden of HCV-related disease and costs from a Canadian perspective. Methods Using a system dynamic framework, the authors quantified the HCV-infected population, disease progression and costs in Canada between 1950 and […]
-
Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas
Summary Background Globally, hepatitis C virus (HCV) infects ~3% of the population. The objective of this study was to review published work and determine the direct medical costs for diseases associated with HCV infection globally, with the exception of the US. Methods A systematic literature search was conducted to identify studies reporting the costs of […]
-
Economic burden of hepatitis C-associated diseases in the United States
Summary There are approximately 100 drugs in development to treat hepatitis C. Over the next decade, a number of new therapies will become available. A good understanding of the cost of hepatitis C sequelae is important for assessing the value of new treatments. The objective of this study was to assess the economic burden data […]
English 
Spanish 
French 
Chinese 
Russian 
Arabic